Zegerid sales force
This article was originally published in The Tan Sheet
Executive Summary
Santarus looks to build commercial presence for its proton pump inhibitor Zegerid with a sales force expansion announced Oct. 24. Santarus and Schering-Plough announced plans to switch the product from Rx to OTC earlier this month (1"The Tan Sheet" Oct. 23, 2006, p. 3). Approximately 150 sales representatives are expected to be added to the team, which will bring the total number of first detail sales reps to over 500, the firm says. Weekly prescriptions have been growing by 135% since the launch of Zegerid capsules, according to President and CEO Gerals Proehl. "Moreover, our experience indicates that the frequency in delivering a consistent message about Zegerid's clinical benefits is key to increasing awareness and positively impacting physician prescribing behavior," he added. The new sales reps are anticipated to be trained and in place by the end of the first quarter of 2007, with the help of a contract sales organization...